A record of refrigeration does not, by itself, establish that a preparation still meets its specifications. Storage conditions are one part of a stability assessment, not a substitute for testing. The distinction is especially important when a forum supplies a universal shelf life for many unrelated peptides.
The FDA's explanation of expiration dating connects drug storage conditions and expiration dates to stability evidence. It does not supply a shelf life for a no-DAC CJC/ipamorelin research blend.
Which attributes are still acceptable?
The amount of intact peptide is only one question. A product assessment may also need to address degradation products, physical changes and microbiological quality. A clear-looking solution cannot demonstrate that all of those attributes remain acceptable.
Dry material and a prepared solution are also different test articles. Data for one state do not automatically validate the other. A blend introduces another question: both ingredients and the combined formulation must be considered, rather than assuming that each retains the stability reported separately.
A date on an old certificate describes the tested sample at the time and under the stated conditions. It is not continuous monitoring of a vial's later history. Unknown temperature excursions, packaging changes or handling cannot be reconstructed from appearance alone.
The safe editorial response to “is it still good?” is therefore not a guessed number of weeks or months. It is an explanation of what product-specific evidence would be needed and why generic forum rules cannot certify the material.
For a prescribed medicine, a pharmacist can evaluate the applicable manufacturer's information and storage history. A research-only preparation should not be treated as a medicine simply because it was kept cold. This article gives no salvage, freezing, remixing or administration instructions. Uncertainty about an old vial's quality cannot be resolved by testing whether it produces a sensation.